Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | NUDT6 |
| Gene Name: | NUDT6 |
| Protein Full Name: | Nucleoside diphosphate-linked moiety X motif 6 |
| Alias: | Antisense basic fibroblast growth factor;Protein GFG |
| Mass (Da): | 35679 |
| Number AA: | 316 |
| UniProt ID: | P53370 |
| Locus ID: | 11162 |
| COSMIC ID: | NUDT6 |
| Gene location on chromosome: | 4q28.1* |
| Cancer protein type: | OP/TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.13 |
| Normal role description: | NUDT6 is nudix hydrolase, capable of hydrolyzing a broad range of nucleoside diphosphates linked to other moieties. Its expression is inversely related to FHF2 and it is thought to function as an FGF2 antisense transcript (high levels of FGF2 are associated with the proliferation of smooth muscle in atherosclerosis and with tumour proliferation). In the pituitary, NUDT6 has been found to have various hormone-regulatory and anti-proliferative actions independent of FGF2 expression, and may thus function as a tumour suppressor there. In esophageal adenocarcinomas, the overexpression of the gene is associated with increased survival rates, also supporting its role as a TSP. However, in colorectal cancer NUDT6 overexpression has been demonstrated to increase cell proliferation, and in malignant melanoma the gene is believed to be involved in promoting its self-renewal and tumour cell plasticity, as well as in the development of the endothelia-lined vasculature. |
| Commentary on involvement of protein in cancer: | * Chromosome location = 4q26 according to NCBI Gene |